Ani Pharmaceuticals (ANIP) Common Equity (2010 - 2026)

Ani Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting $562.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $562.3 million, up 15476.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $562.3 million (up 15476.18% YoY), and the FY2025 annual result was $540.7 million, up 27036100.0% from the prior year.
• Common Equity came in at $562.3 million for Q1 2026 at Ani Pharmaceuticals, up from $540.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $562.3 million in Q1 2026 to a low of -$89.6 million in Q3 2024.
• The 5-year median for Common Equity is $2000.0 (2023), against an average of $135.8 million.
• Across the five-year window, Common Equity surged 52362700.0% in 2024 and tumbled 3843200.0% in 2025, its largest moves.
• Ani Pharmaceuticals' Common Equity stood at -$5.1 million in 2022, then jumped by 10192.32% to $514.1 million in 2023, then plunged by 100.0% to $2000.0 in 2024, then surged by 27036100.0% to $540.7 million in 2025, then increased by 3.99% to $562.3 million in 2026.
• The last three Common Equity figures came in at $562.3 million (Q1 2026), $540.7 million (Q4 2025), and $505.8 million (Q3 2025), per Business Quant data.